8.7 pmol ( p = 0.036). There was an increase in 3-ClY mean from 0.81 ± 0.36 mmol/mol-tyrosine in stage 1 to 1.42 ± 0.41 mmol/mol-tyrosine in stage 5 ( p < 0.001). The mean 3-ClY levels in patients with and without CAD were 1.25 ± 0.44 and 1.04 ± 0.42 mmol/mol-tyrosine ( p = 0.023), respectively. C-statistic of ClY when added to myeloperoxidase level to predict CKD stage 5 was 0.86, compared to 0.79 for the myeloperoxidase level alone ( p = 0.0097). Conclusion: The myeloperoxidase levels decrease from stages 1 to 5, whereas activity increases. In contrast, both myeloperoxidase and ClY levels rise in the presence of CAD at various stages of CKD. Measuring both plasma myeloperoxidase and 3-CLY levels provide added value to determine the burden of myeloperoxidase-mediated oxidative stress.
cannot entirely explain the rate and risk of cardiovascular outcomes in CKD [9] . Atherosclerosis is an inflammatory disorder characterized by oxidative stress, which leads to coronary artery disease (CAD) [10, 11] . This is of particular importance in diseases such as CKD where chronic inflammation initiates and propagates further oxidative stress. Myeloperoxidase, a phagocytic heme enzyme, is a major source of reactive oxidants in the human vasculature [11] , and has been widely implicated in the development of atherosclerotic lesions. In an initial large epidemiologic study, the level of plasma myeloperoxidase was a strong independent predictor of CAD [12] , and recent clinical studies have both supported and refuted the strength of this association [13] [14] [15] . Further, myeloperoxidase has been localized to atherosclerotic plaques, and oxidants produced by myeloperoxidase activate protease cascades and plaque rupture [16, 17] . The mechanisms linking myeloperoxidase and CKD-atherosclerosis are incompletely defined, and how plasma levels of myeloperoxidase link with its activity are not entirely understood.
Myeloperoxidase is a highly abundant iron-containing heme protein that is encoded by 14 kb gene located on the chromosome 17q23.1 [18] . The proteolytic form of the enzyme is 146 kDa, which is most abundant in phagocytic cells [19, 20] . Myeloperoxidase uses H 2 O 2 and chloride to generate the powerful oxidant hypochlorous acid (HOCl). The importance of this reaction is underscored by the presence of enzymatically active myeloperoxidase in human atherosclerotic lesions [21] . Although most oxidation products generated by HOCl are either nonspecific or yield uninformative compounds, in vitro and in vivo human and model system studies demonstrate that myeloperoxidase converts tyrosine into 3-chlorotyrosine (3-ClY), a stable product [22] [23] [24] [25] [26] [27] [28] [29] [30] . Cumulative body of evidence suggests a higher rate of adverse cardiovascular outcomes in association with higher plasma levels of myeloperoxidase in non-CKD patient population, which may reveal a role for its prognostic value in risk stratification [12, 31, 32] . In a prospective cohort of 885 selective coronary artery angiography followed for 13 years for cardiovascular mortality outcome, elevation of myeloperoxidase was associated with 5.3-fold higher mortality risk [31] . In a case-control observation nested in the European Prospective Investigation into Cancer and Nutrition study with 8 years of follow-up, elevated myeloperoxidase levels predicted risk of future CAD in healthy individuals [32] . In another case-control study comparing angiography proven established CAD with individuals without CAD, both leukocyte and blood myeloperoxidase levels were higher in the presence of CAD [12] .
CKD is associated with substantial fatal and nonfatal cardiovascular morbidities, impacting people with and without previously known clinical cardiovascular diseases [33] . Importantly, as CKD severity increases, CAD risk markedly increases. It is unclear if myeloperoxidase activity and level could in part explain the added cardiovascular burden in advancing CKD, as the association of myeloperoxidase level with different stages of CKD has not been systematically investigated. Although studies suggest higher rate of mortality and cardiovascular outcomes in association with higher myeloperoxidase levels in dialysis patients [34, 35] , other studies show normal or even decreasing level of myeloperoxidase at higher stages of CKD [36, 37] . Such a discrepancy in myeloperoxidase distribution by CKD stage may be a reflection of dissociation between myeloperoxidase level and its activity in non-dialysis CKD patients. We hypothesized that myeloperoxidase-specific protein-bound 3-ClY, a specific marker of myeloperoxidase activity, would predict the severity of CKD and CAD risk better than myeloperoxidase levels alone. To our knowledge, such a study has not been conducted in a human CKD population.
Materials and Methods

Patients
This study utilizes the Clinical Phenotyping Resource and Biobank Core (CPROBE) of the George M. O'Brien Translational Core Center. CPROBE is a multicenter observational cohort of adult and pediatric participants with CKD stages 1 to 5 recruited from the University of Michigan (Ann Arbor, MI, USA), Renaissance Renal Research Institute (Detroit, MI, USA), Wayne State University (Detroit, MI, USA), John H Stroger Hospital (Chicago, IL, USA), Temple University (Philadelphia, PA, USA), and Levine Children's Hospital (Charlotte, NC, USA). Patients' demographic, socioeconomic, and clinical information are collected, along with blood and urine biosamples, at enrollment and annually, thereafter. Biosamples, stored in a centralized biobank, are available for translational research. Overall, 111 C-PROBE participants with available clinical data and serum samples, and frequency matched by race were selected from 5 stages of CKD. The presence of CAD was defined as previous history of unstable angina, acute myocardial infarction or history of revascularization with angioplasty, stenting or coronary artery bypass grafting. Baseline clinical and laboratory data were used. CKD-EPI formula was used to calculate estimated glomerular filtration rate (eGFR). Stored plasma samples from enrolled patients were obtained for myeloperoxidase and oxidized amino acid measurements.
Myeloperoxidase Measurement
Myeloperoxidase was quantified in plasma samples with a commercial sandwich enzyme-linked immunosorbent assay kit (Biolegend, San Diego, CA, USA). All samples were run in duplicate, and the sample average value is expressed as pmol plasma.
Mass Spectrometry Analysis
Protein-bound 3-ClY, a marker for myeloperoxidase activity, was measured by liquid chromatography-electrospray ionization tandem mass spectrometry as described previously [24] . Plasma protein was precipitated with ice-cold trichloroacetic acid (10% vol/vol) and diluted in 50 m M phosphate buffer pH 7.4. The protein precipitate was delipidated with water/methanol/waterwashed diethyl ether (1: 3:7; vol/vol/vol). Known concentrations of isotopically labeled internal standards 13 C 6 tyrosine, 13 C 9 15 N 1 tyrosine, and 13 C 6 3-chlorotyroine were added, and samples were hydrolyzed for 24 h in 4 N methane sulfonic acid treated with benzoic acid. Following extraction with Supelclean ENVI ChromP columns (3 mL, Supelco Inc., Bellefonte, PA, USA), ClY levels were quantified by liquid chromatography-electrospray ionization tandem mass spectrometry with multiple reaction monitoring positive ion acquisition mode, as described previously, utilizing an Agilent-6410 triple-quadrupole MS system equipped with an Agilent 1200 LC system [38, 39] . Labeled precursor amino acid, 13 C 9 15 N 1 tyrosine, was added to monitor potential internal artifact formation of 3-ClY and was noted to be negligible. ClY levels were normalized for precursor amino acid tyrosine and expressed as ClY mmol/mol tyrosine.
Other Laboratory Values
For measuring plasma lipid profile, Daytona chemistry analyzer series were used with the following details; for total plasma cholesterol enzymatic assay using Randox RX Series CH-3810; for total plasma triglyceride GPO-PAP method using RX Series TR-3823; for plasma low-density lipoprotein and high-density lipoprotein (HDL), a 2-step process including elimination of chylomicron and other lipoproteins followed by quantification using Randox RX Series CH-3841 and CH-3811, respectively. Colorimetric method was applied to measure serum creatinine, serum albumin (using bromocresol green), and urine protein (using pyrogallol red). White blood cells in blood were measured by Sysmex XN9000.
Quality Control
The myeloperoxidase levels were measured in duplicate, and the overall intra-assay coefficient of variation (CV) was 2.47%. For ClY measurement and to assess the drift in mass spectrometer over time, a pooled plasma sample was run at the beginning and then after run of every 10 samples. The intra-assay CV of MS spectra for tyrosine and ClY were 8.96 and 9.74%, respectively.
Statistical Analysis
Independent t test and analysis of variance (ANOVA) were used to compare the mean of continuous variables in 2 and more than 2 groups, respectively. The distribution of categorical variables by stages of CKD and CAD were tested using chi-square test. Analysis of covariance was applied to evaluate the effect of covariates on the mean of myeloperoxidase and ClY levels by stages of CKD, as well as by the presence of CAD across stages of CKD. Logistic regression analysis was applied to estimate the risk of CAD by change in myeloperoxidase and ClY levels in adjusted models. Probabilistic scores of myeloperoxidase and ClY levels and their combination to predict CAD and CKD stage 5 were calculated using logistic regression models. We generated receiver operating characteristic curves to predict CAD and CKD stage 5 from the aforementioned probabilistic scores and compared the corresponding c-statistic with each other. This study has 89% power to detect 8 pmol myeloperoxidase difference with SD = 7 at alpha = 0.05, using a 2-sided ANOVA test. Similarly, the study has over 95% power to detect 0.6 mmol/mol tyrosine difference in ClY level with SD = 0.6 at alpha = 0.05, using a 2-sided ANOVA test. Table 1 . There was a significant increase in the linear trend of age, systolic blood pressure, male gender, diabetes, hypertension, and use of aspirin, statins, and calcium channel blockers from stage 1 to stage 5 of CKD ( p < 0.05). Table 2 compares the characteristics of patients by the presence of CAD. Participants with CAD on average were older, had higher systolic blood pressure but lower eGFR, were more likely to have hypertension and heart failure, and had a higher percentage use of aspirin, statins, and calcium channel blockers ( p < 0.05). Figure 1 a shows the unadjusted distribution of myeloperoxidase levels measured by enzyme-linked immunosorbent assay according to CKD stage. Surprisingly, there is a significant decline in the linear trend of myeloperoxidase from CKD stage 1 to stage 5 ( p = 0.003). The unadjusted mean ± SD of myeloperoxidase decreased from 18.8 ± 12.3 pmol in stage 1 to 10.5 ± 4.7 pmol in stage 5 ( p = 0.034). After adjusting for the differentially distributed covariates at baseline ( Table 1 ) , the adjusted values remained similar to unadjusted values with the mean ± SD of myeloperoxidase of 18.1 ± 12.3 pmol at stage 1 and 10.9 ± 4.7 pmol at stage 5 ( p = 0.011). Figure 1 b shows that within each stage of CKD, participants with CAD had a trend toward higher myeloperoxidase levels, although the difference did not reach statistical significance within each CKD stage. However, Figure 1 c shows that overall the CKD adjusted mean ± SD of myeloperoxidase in patients with CAD was 19.1 ± 10.1, which was significantly higher compared to 14.8 ± 8.7 pmol in patients without CAD ( p = 0.036). Logistic regression model revealed that each 10 pmol increase in myeloperoxidase was associated with 1.91-fold (95% CI 1.09-3.36, p = 0.025) higher odds of association with CAD, after adjusting for eGFR, diabetes, hypertension, gender, use of aspirin, calcium channel blockers, and statins. No difference was observed in myeloperoxidase level by diabetes status.
Results
Baseline Characteristics
Myeloperoxidase Levels by CKD and CAD
ClY by CKD and CAD
In contrast to myeloperoxidase levels, there was a significant increase in the linear trend of ClY from stage 1 to stage 5 CKD ( p < 0.001; Fig. 1 d) . The adjusted mean ± SD of ClY increased from 0.81 ± 0.36 mmol/mol tyrosine in stage 1 to 1.41 ± 0.41 mmol/mol tyrosine in stage 5 ( p < 0.001). Figure 1 e shows that the ClY level in patients with CAD was higher than those without CAD in CKD stages 1, 3, and 4 ( p ≤ 0.031). Similarly, Figure 1 f shows that after multivariable adjustment (including CKD stages), the overall ClY level in patients with and without CAD was 1.25 ± 0.44 and 1.04 ± 0.42 mmol/mol tyrosine ( p = 0.023), respectively. Logistic regression model revealed that increase of each 1 mmol of ClY/mol tyrosine was associated with 3.83-fold (95% CI 1.09-13.47, p = 0.026) higher odds of association with CAD, after adjusting for eGFR, diabetes, hypertension, gender, use of aspirin, calcium channel blockers, and statins. No difference was observed in ClY level by diabetes status. 
Discussion
In this study, we observed a graded decrease in crude and adjusted myeloperoxidase level by stage of CKD. In contrast, the ClY level increased with increasing severity of CKD, suggesting a discrepancy between the 2 measures in CKD subjects. Myeloperoxidase and ClY levels were higher in patients with a prior history of CAD.
Increased risk of mortality and cardiovascular outcomes in end-stage kidney disease (ESKD) patients is shown in previous studies [34, 35] . In an observation of 356 hemodialysis patients, Kalantar-Zadeh et al. [34] showed that the highest tertile of myeloperoxidase was associated with 82% higher risk of mortality as compared to the middle tertile. In another study in ESKD patients on peritoneal dialysis, Wang et al. [35] showed that doubling of myeloperoxidase was associated with 46 and 60% higher adjusted risk of mortality and cardiovascular events, respectively. On the contrary, controversial reports on myeloperoxidase level at milder stages of CKD have raised question about its prognostic value at milder stages of CKD. In an observation of 41 non-dialysis CKD patients, Caimi et al. [37] did not see any significant association between myeloperoxidase circulating levels and serum creatinine or GFR. In another observation of 100 patients at different stages of CKD, Madhusudhana et al. [36] reported a graded decrease in plasma myeloperoxidase from stage 1 to stage 5. This is in contrast with the report of Capeillere-Blandin et al. [40] who showed a significantly higher level of myeloperoxidase in ESKD patients on hemodialysis when compared to non-dialysis CKD patients. Increase in myeloperoxidase after hemodialysis [41] , its differential regulation by hemodialysis membrane type [42, 43] , duration of dialysis, and variation in background variables such as anthropometric measures [44] , comorbidities, and medication use suggest their confounding rules in myeloperoxidase level [45] . The change in 3-ClY is less frequently studied in CKD. In a case-control observation, Himmelfarb et al. [46] matched 5 hemodialysis patients by age and sex with 5 healthy controls. While the oxidized amino acid was detected in 4 out of 5 dialysis patients, the level was undetectable in healthy controls [46] . Our findings can align with this conflicting literature in that while the myeloperoxidase level was lower in our patients with more advanced CKD, compatible with Madhusudhana's report, the ClY level increased by worsening of CKD stage and was independently associated with CAD.
In our study, myeloperoxidase and ClY levels were discordant, raising concern of measuring myeloperoxi- p value of linear trend: * p < 0.05, ** p < 0.01, *** p ≤ 0.001. † Values are median and interquartile range. SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; CAD, coronary artery disease; PAD, peripheral artery disease; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; LDL, low density lipoprotein; HDL, high density lipoprotein; UPCR, urine protein creatinine ratio; WBC, white blood cell; eGFR, estimated glomerular filtration rate.
Afshinnia et al. 78 dase levels alone in isolation. This discrepancy might indicate that the plasma myeloperoxidase levels may not fully reflect the myeloperoxidase burden. Lack of significant inverse correlation between the 2 measures indicates that the increased ClY level is not simply from the shift of myeloperoxidase utilization. This raises potential additional mechanisms. Myeloperoxidase deficiency is categorized into 2 forms including primary or congenital, and secondary or acquired [47] . Among the acquired etiologies of myeloperoxidase deficiency, diabetes mellitus, iron deficiency, thrombotic diseases, kidney transplantation, severe infectious diseases, neuronal lipofus- cinosis, lead intoxication, hematological malignancies, metastatic cancers, medications (including cytotoxic agents and anti-inflammatory compounds), and pregnancy are reported [47] . CKD is characterized by a constellation of several of the above mentioned comorbidities and complications and therefore may lead to lower myeloperoxidase plasma levels. However, the mechanism of reduction of circulating myeloperoxidase remains unclear in these secondary states. ClY level, on the contrary, may reflect the overall myeloperoxidase burden more accurately. Extravascular myeloperoxidase (derived from macrophages and inflammatory cells in sites of inflammation including vasculature) may participate in oxidation reactions but may not contribute to plasma myeloperoxidase. We previously reported that HDL 3-ClY content from atheroma was substantially higher than those in plasma-derived HDL in subjects with cardiovascular disease (CVD) [29, 30] . In recent studies, we also showed that myeloperoxidase levels and activity in plasma might be discordant in subjects with rheumatoid arthritis and lupus, suggesting myeloperoxidase may be modifying plasma proteins in plasma and in extravascular sites, such as inflamed tissue or vasculature [25, 26] . Furthermore, in this study we show that myeloperoxidase and ClY together predict the severity of CKD better than each of the individual measures alone. Although the c-statistic of myeloperoxidase activity or its combination to predict CAD was higher than the c-statistic of myeloperoxidase alone, the difference did not reach statistical significance. Altogether, these observations support the hypothesis that myeloperoxidase oxidation markers of circulating plasma proteins may reflect added myeloperoxidase burden. Thus, a combined measurement of both myeloperoxidase and ClY levels might serve as mechanistic markers of CKD severity and CAD risk in this high-risk population.
This study has several strengths. We took advantage of existing well-characterized CKD patients in CPROBE cohort, which allowed correlating the biomarkers with phenotypes. This is also one of the largest studies in CKD patients investigating not only myeloperoxidase level but also its stable end-product ClY. In fact, this approach has revealed the association of ClY with CAD despite the decrease of myeloperoxidase level by CKD stage, which was viewed as a controversial matter. This study is adequately powered to test the hypothesis. This study also has limitations. The utility of myeloperoxidase and ClY as a diagnostic or predictive biomarker in clinical practice is not ascertained by this work, as we have not compared the classification power of myeloperoxidase or ClY with wellestablished traditional biomarkers in clinical practice to diagnose CKD or predict its progression or CVD outcomes. The significance of our findings is in providing further insight on the inflammatory mechanism of CKD and highlighting a potential target for future studies. By design, this is a cross-sectional observation which does 80 not establish causality. Although it is possible that there may be unmeasured residual confounders in the cohort, it is our assessment that the strongest indicator of health status in the cohort is CKD stage, which is already used for adjustment. Therefore, the potential for further residual confounders to substantially alter the observed relationships is low. As this was not a longitudinal study, the predictive power of myeloperoxidase and ClY to estimate mortality outcome was not achieved. We would also like to highlight that the samples used in this study are 7 years old, which in our assessment is within the time frame of preserved stability given the minimum number of freeze-thaw cycles. In addition, measurement of protein-bound ClY reflects an indirect measurement of myeloperoxidase activity. Although very few human enzymes are able to produce the oxidant HOCl, we recognize that this study does not provide a direct measurement of myeloperoxidase activation. Another limitation is that CAD was based on known cases and there may be some undiagnosed subclinical disease. Finally, the conclusions drawn from this study are specific to patients included in this cohort, and we are conscious that patients with different comorbidities and/or causes of CKD could have different myeloperoxidase profiles. Whether or not myeloperoxidase inhibitors may alter the CVD outcome and impact survival would form the scope of further future studies.
In conclusion, this study provides evidence for increase of ClY level by worsening stage of CKD, despite decrease in the level of myeloperoxidase at advanced CKD stage, showing its added value beyond myeloperoxidase level to predict severity of CKD. It also provides evidence for independent association of myeloperoxidase and ClY levels with CAD in CKD patients. Our results confirm the hypothesis that ClY levels correlate with CKD stage and known CAD in this vulnerable population and raise the possibility that measurement of ClY, rather than myeloperoxidase levels, might serve as a mechanistic marker for CKD progression and CAD risk.
